Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 5/20 | 0.48 |
| ▸ | HSD11B2 | P80365 | 5/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3112463 | 0.91 | HSD11B1 (0.50) | HSD11B1HSD11B2EPHX2 | |
| SCHEMBL3123120 | 0.90 | CYP17A1 (0.44) | HSD11B1HSD11B2EPHX2HPGDCYP17A1 | |
| SCHEMBL1846642 | 0.83 | HSD11B1 (0.56) | HSD11B1HSD11B2EPHX2HPGDALDH1A1 | |
| SCHEMBL1846641 | 0.83 | HSD11B1 (0.56) | HSD11B1HSD11B2EPHX2HPGDALDH1A1 | |
| SCHEMBL1845687 | 0.83 | HSD11B1 (0.56) | HSD11B1HSD11B2EPHX2HPGDALDH1A1 | |
| SCHEMBL2825063 | 0.83 | HSD11B1 (0.56) | HSD11B1HSD11B2EPHX2HPGDALDH1A1 | |
| SCHEMBL12578487 | 0.83 | HSD11B1 (0.56) | HSD11B1HSD11B2EPHX2HPGDALDH1A1 | |
| SCHEMBL2839601 | 0.80 | HSD11B1 (0.52) | HSD11B1HSD11B2EPHX2ALDH1A1 | |
| SCHEMBL1844036 | 0.74 | HSD11B1 (0.57) | HSD11B1HSD11B2EPHX2 | |
| SCHEMBL1844038 | 0.74 | HSD11B1 (0.57) | HSD11B1HSD11B2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222417-B2 | Compound having 11β-HSD1 inhibitory activity | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2012-07-17 | — | — | US | disclosed |
| US-20100179325-A1 | COMPOUND HAVING 11BETA-HSD1 INHIBITORY ACTIVITY | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-07-15 | — | — | US | disclosed |
| EP-2172453-A1 | COMPOUND HAVING 11 ß-HSD1 INHIBITORY ACTIVITY | Taisho Pharmaceutical Co. Ltd. (JP) | 2010-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179325-A1 | COMPOUND HAVING 11BETA-HSD1 INHIBITORY ACTIVITY | HSD11B1, CYP4A11, HSD11B2 | HSD11B1 1/4885HSD11B2 3/4885EPHX2 2538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.